1. Home
  2. CGON vs FTF Comparison

CGON vs FTF Comparison

Compare CGON & FTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • FTF
  • Stock Information
  • Founded
  • CGON 2010
  • FTF 2003
  • Country
  • CGON United States
  • FTF United States
  • Employees
  • CGON N/A
  • FTF N/A
  • Industry
  • CGON
  • FTF Finance/Investors Services
  • Sector
  • CGON
  • FTF Finance
  • Exchange
  • CGON NYSE
  • FTF Nasdaq
  • Market Cap
  • CGON 2.3B
  • FTF 1.9B
  • IPO Year
  • CGON 2024
  • FTF N/A
  • Fundamental
  • Price
  • CGON $27.85
  • FTF $6.64
  • Analyst Decision
  • CGON Strong Buy
  • FTF
  • Analyst Count
  • CGON 10
  • FTF 0
  • Target Price
  • CGON $65.11
  • FTF N/A
  • AVG Volume (30 Days)
  • CGON 430.1K
  • FTF 153.9K
  • Earning Date
  • CGON 03-04-2025
  • FTF 01-01-0001
  • Dividend Yield
  • CGON N/A
  • FTF 11.45%
  • EPS Growth
  • CGON N/A
  • FTF N/A
  • EPS
  • CGON N/A
  • FTF N/A
  • Revenue
  • CGON $684,000.00
  • FTF N/A
  • Revenue This Year
  • CGON $158.34
  • FTF N/A
  • Revenue Next Year
  • CGON N/A
  • FTF N/A
  • P/E Ratio
  • CGON N/A
  • FTF N/A
  • Revenue Growth
  • CGON 258.12
  • FTF N/A
  • 52 Week Low
  • CGON $25.77
  • FTF $5.76
  • 52 Week High
  • CGON $47.78
  • FTF $6.56
  • Technical
  • Relative Strength Index (RSI)
  • CGON 41.49
  • FTF 49.19
  • Support Level
  • CGON $27.10
  • FTF $6.62
  • Resistance Level
  • CGON $29.42
  • FTF $6.68
  • Average True Range (ATR)
  • CGON 1.15
  • FTF 0.05
  • MACD
  • CGON -0.10
  • FTF -0.00
  • Stochastic Oscillator
  • CGON 29.02
  • FTF 42.31

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About FTF Franklin Limited Duration Income Trust of Beneficial Interest

Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.

Share on Social Networks: